Vironova signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS).
In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body. Vironova Analyzing Software (VAS) in combination with Cryo-transmission electron microscopy (cryoTEM) enables semi-automated image analysis of liposomes, providing accurate, reproducible and timely results.
“Beta-testing is designed to help us accelerate development and improve the robustness and user friendliness of VAS. This is a very valuable compliment to the input from our internal microscopists who work with liposome characterization,” says Nina Ewerlöf, Head of Vironova instruments and software.